United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

4:35pm BST
Change (% chg)

€1.70 (+1.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rosenberg, A.A. 

Mr. A.A. Rosenberg has served as Non-Executive Independent Member of the Board at argenx SE since April 2017. He currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions. Mr. Rosenberg has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 until February 2015, he served as Corporate Head of M&A and Licensing at Novartis Pharma. He served as Global Head of Business Development and Licensing at Novartis Pharma from March 2005 to December 2012. Msc. A. A. Rosenberg holds non-executive board memberships in Idenix Pharmaceuticals, Radius Health Inc., TriNetX, Inc., Clinical Ink, Inc., iOmx Therapeutics AG and Cullinan Oncology Inc. Msc. A. A. Rosenberg has a B. Sc. (Hons) from the University of Leicester and a M. Sc. Physiology from the University of London. He is member of Audit committee.

Basic Compensation

Total Annual Compensation, EUR 42,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 42,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --